Kaigo Health vs Idexx Laboratories
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kaigo Health (YC F25) deploys AI voice agents for elderly outpatient follow-up, scaling post-visit check-ins 100x for Medicare providers who currently have near-zero between-visit care.
About
Kaigo Health is a healthcare AI startup founded in 2025 and headquartered in San Francisco, built to address one of the most persistent gaps in outpatient elderly care: the near-complete absence of structured follow-up between clinical visits. The company was accepted into Y Combinator's Fall 2025 batch, a validation of its founding team and market thesis at a very early stage. Kaigo targets the Medicare provider ecosystem, where outpatient follow-up is both a quality metric and a reimbursement driver under value-based care arrangements.\n\nKaigo's platform deploys AI voice agents that conduct follow-up calls with elderly patients between clinical encounters, checking on medication adherence, symptom changes, and overall wellbeing in a conversational, accessible format appropriate for older adults who may be less comfortable with app-based or text communication. The system scales these follow-up touchpoints by 100x compared to what a human care coordination team could accomplish at equivalent cost, dramatically expanding the reach of providers who want to improve patient engagement without proportional staffing increases.\n\nThe company is entering a market shaped by twin pressures: an aging US population driving record Medicare enrollment and a care workforce shortage that makes scaling high-touch care coordination through humans alone economically unsustainable. AI voice agents are increasingly recognized as a practical solution to this gap, particularly for the elderly population where voice interaction is natural and phone calls remain a trusted communication channel. Kaigo's early YC backing positions it alongside a cohort of companies building AI infrastructure for the future of value-based elder care.
Veterinary diagnostics leader with $3.81B FY2024 revenue; 130,000+ analyzer installed base; AI-powered inVue Dx digital cytology; VetConnect data platform; pet humanization tailwind.
About
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headquartered. The company trades on Nasdaq (IDXX) and reported $3.81 billion in revenues for FY2024, maintaining its dominant position in point-of-care veterinary diagnostics through an installed base of over 130,000 Catalyst chemistry analyzers, ProCyte hematology systems, and SNAP rapid assay devices deployed in veterinary clinics worldwide. CEO Jay Mazelsky has continued IDEXX's expansion into AI-powered diagnostics and digital pathology, building on over four decades of veterinary-specific product development.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.